Palopegteriparatide record · updated 18h ago

Healing & recoveryMuscle & body compGrade A · human clinicalResearch use only

All 3 studies Jump to the evidence Compare

What is Palopegteriparatide used for?

Research peptide discovered via AI researcher. peptide analogue

Primarily researched for · Healing & recovery

Development stage

where Palopegteriparatide sits between preclinical work and regulatory approval

1Cleared
Preclinical
Animal / in-vitro work
2Cleared
Phase 1
Safety in humans
3Cleared
Phase 2
Efficacy signal
4Cleared
Phase 3
Confirmatory trials
5Current
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 23 registered trials. It describes the research record, not a recommendation.

Identity

NamePalopegteriparatide

Chain length—

Molecular weight—

Formula—

Structure type—

ClassHealing

Research levelEmerging

Discovered byThe Librarian · 2026

Pharmacology

Mechanism—

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence—

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 4, 2026. How this works →

Research stats

Total studies3

Human / animal / cellular3 / 0 / 0

Highest trial phasePhase 4

Years covered2023–2026

Latest study1mo ago

Publication history

20232026

Research funding

—no NIH grants found

Safety signals

FAERS reports39

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 3 Semantic Scholar UniProt

Study register

3 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Clinical Outcomes of Colorectal Endoscopic Full-Thickness Resection Using the Full-Thickness Resection Device: A Multicenter Study. FindingTechnical success achieved in 89% of cases.	Human	2023	Full text read0.80
Adverse Pathological Features and Worse Prognosis in Rectal Cancer Compared With Colon Cancer in T1 and T2 Stages. FindingT1 rectal cancer had 4.4% recurrence rate vs 0.6% in colon cancer, p<0.05.	Human	2023	Full text read0.80
Spinal versus general anaesthesia and serious complications in older patients undergoing hip fracture surgery in Germany: a multicentre randomised clinical trial. FindingThe primary composite outcome did not differ between the two anaesthetic techniques (centre-stratified hazard ratio: 1·23, 95% CI 0·83-1·82; p=0·29).	Human	2026	Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Palopegteriparatide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Palopegteriparatide is discussed should be drawn from it.